Loading...
Market
Who will be AstraZeneca's CEO by the end of 2024?
4
Resolution / Starting Odds
Pascal Soriot • 25%
New CEO • 25%
Interim CEO • 25%
Other • 25%
Company press releases and news reports
Story
AstraZeneca Overturns $107.5 Million Verdict in Patent Dispute with Pfizer
Aug 14, 2024, 07:00 PM
AstraZeneca has successfully overturned a jury verdict that required the company to pay $107.5 million for infringing cancer-drug patents owned by Wyeth, a subsidiary of Pfizer. The decision was made by a federal judge in Delaware, marking a significant legal victory for AstraZeneca. Pfizer, which acquired Wyeth in 2009, initially filed the lawsuit against AstraZeneca in 2021. This outcome is seen as a milestone decision for UK companies, particularly for AstraZeneca's CEO Pascal Soriot and the shareholders who supported his vision.
View original story
Similar markets
Albert Bourla • 25%
Current Pfizer executive • 25%
External candidate • 25%
Other • 25%
Internal candidate • 25%
External candidate from a major pharmaceutical company • 25%
External candidate from a biotech startup • 25%
Other • 25%
Boehringer Ingelheim • 25%
AstraZeneca • 25%
Another major pharmaceutical company • 25%
A biotech startup • 25%
Executive A • 25%
Executive B • 25%
Both • 25%
Neither • 25%
Current CEO remains • 33%
New CEO appointed • 33%
Interim CEO appointed • 33%
Current CEO (Alan Jope) • 25%
New CEO from within Unilever • 25%
New CEO from outside Unilever • 25%
Interim CEO • 25%
Elon Musk • 25%
Linda Yaccarino • 25%
A new CEO • 25%
No CEO (Interim or Acting) • 25%
